Explore Top Pharmaceutical Products, APIs, Formulations & Intermediates from Verified Suppliers

Paracetamol (Acetaminophen) Injection

Strength:
1000 mg/100 mL (10 mg/mL)

Form: Injectable solution

Reference Brands: Ofirmev

View More Get Enquiry

Ceftriaxone Injection

Strength:
250 mg, 1 g, and 2 g

Form: Lyophilized powder/ Prefilled syringe

Reference Brands: Rocephin

View More Get Enquiry

Itraconazole Pellets

Strength:
100 mg or 200 mg

Form: Pellets

Reference Brands: Sporanox

View More Get Enquiry

Lansoprazole Pellets

Strength:
15 mg and 30 mg

Form: Pellets

Reference Brands: Prevacid

View More Get Enquiry

Darleukin Injection

Strength:
A standardized dose of 120 million adipose-derived stem cells per injection

Form: Intralesional injection

Reference Brands: Alofisel(US & EU)

View More Get Enquiry

Etranacogene Dezaparvovec. Infusion

Strength:
Single infusion product designed to produce sustained factor IX levels in hemophilia B patients, dosage individualized based on patient weight

Form: Intravenous infusion

Reference Brands: Hemgenix (US & EU)

View More Get Enquiry

Elivaldogene Autotemcel Infusion

Strength:
A personalized gene therapy designed to halt or slow ALD progression, dosed based on weight, administered as a single infusion in specialized treatment centers

Form: Intravenous infusion

Reference Brands: Skysona(US & EU)

View More Get Enquiry

Valoctocogene Roxaparvovec Infusion

Strength:
A single-dose gene therapy designed to increase factor VIII production in hemophilia A patients

Form: Intravenous infusion

Reference Brands: Roctavian(US & EU)

View More Get Enquiry

Voretigene Neparvovec Infusion

Strength:
Adeno-associated virus (AAV) vector administered via subretinal injection

Form: Subretinal injection

Reference Brands: Luxturna(US & EU)

View More Get Enquiry

Onasemnogene Abeparvovec Injectable

Strength:
Single-dose IV infusion providing 6 x 10^13 vector genomes (vg) per patient

Form: Injectable gene therapy

Reference Brands: Zolgensma(US & EU)

View More Get Enquiry

Idecabtagene Vicleucel Infusion

Strength:
Approved for relapsed/refractory multiple myeloma, with dosing based on patient weight, delivering a personalized, targeted therapy to eliminate cancer cells

Form: IV Infusion

Reference Brands: Abecma(US & EU)

View More Get Enquiry

Lisocabtagene Maraleucel Infusion

Strength:
Approved for relapsed/refractory large B-cell lymphoma, with a standard dose of 100 million CAR T cells per infusion

Form: IV Infusion

Reference Brands: Breyanzi (US & EU)

View More Get Enquiry

Tisagenlecleucel Infusion

Strength:
Single infusion, approved for relapsed/refractory B-cell precursor acute lymphoblastic leukemia (ALL) and diffuse large B-cell lymphoma (DLBCL)

Form: IV Infusion

Reference Brands: Kymriah(US & EU)

View More Get Enquiry

Insulin‑Aspart‑Szjj

Strength:
100 units/mL

Form: SQ Injection

Reference Brands: NovoLog; Merilog is biosimilar to NovoLog.

View More Get Enquiry

Eculizumab‑Aeeb

Strength:
300 mg/20 mL (IV infusion),

Form: Injection for intravenous infusion

Reference Brands: Soliris, Bkemv- Biosimilar of Soliris, Epysqli- Biosimilar of Soliris

View More Get Enquiry

Omalizumab‑Igec

Strength:
75 mg/0.5 mL and 150 mg/mL

Form: Pre filled syringe

Reference Brands: Xolair, Omlyclo - a Biosimilar to Xolair

View More Get Enquiry

Tocilizumab-Bavi

Strength:
80 mg/4ml

Form: Intravenous infusion

Reference Brands: Actemra; Tofidence - biosimilar to Actemra (tocilizumab).

View More Get Enquiry

Denosumab(Others Approved)

Strength:
60 mg, 120 mg

Form: Subcutaneous injection

Reference Brands: Xgeva(US & EU) Ospomyv, Xbryk, Merilog, Stoboclo, Zadenvi, Enwylma, Denbrayce, Izamby - biosimilar to Xgeva

View More Get Enquiry

Denosumab

Strength:
subcutaneous injection

Form: Subcutaneous injection

Reference Brands: Xgeva; Wyost - biosimilar to Xgeva

View More Get Enquiry

Denosumab-Bbdz

Strength:
60 mg, 120 mg

Form: Injection for subcutaneous use

Reference Brands: Prolia(US & EU); Jubbonti - biosimilar to Prolia

View More Get Enquiry

Subscribe to Our Newsletter

Stay updated on pharma trends and marketplace opportunities.

Please enter the correct answer.
This website uses cookies to ensure you get the best experience. By using our site, you agree to our Privacy Policy.